PMC:7299399 / 6057-6302 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T18","span":{"begin":220,"end":227},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"r the first steps of infection, the most common treatment approaches focus on disrupting this key event. At present, there are three main strategies to block ACE2 binding: (i) administration of soluble, recombinant ACE2 protein, which acts as a "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T37","span":{"begin":21,"end":30},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"r the first steps of infection, the most common treatment approaches focus on disrupting this key event. At present, there are three main strategies to block ACE2 binding: (i) administration of soluble, recombinant ACE2 protein, which acts as a "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T58","span":{"begin":69,"end":74},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T59","span":{"begin":243,"end":244},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"r the first steps of infection, the most common treatment approaches focus on disrupting this key event. At present, there are three main strategies to block ACE2 binding: (i) administration of soluble, recombinant ACE2 protein, which acts as a "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T21","span":{"begin":220,"end":227},"obj":"Chemical"}],"attributes":[{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"r the first steps of infection, the most common treatment approaches focus on disrupting this key event. At present, there are three main strategies to block ACE2 binding: (i) administration of soluble, recombinant ACE2 protein, which acts as a "}

{"project":"LitCovid-PubTator","denotations":[{"id":"130","span":{"begin":158,"end":162},"obj":"Gene"},{"id":"131","span":{"begin":215,"end":219},"obj":"Gene"},{"id":"137","span":{"begin":21,"end":30},"obj":"Disease"}],"attributes":[{"id":"A130","pred":"tao:has_database_id","subj":"130","obj":"Gene:59272"},{"id":"A131","pred":"tao:has_database_id","subj":"131","obj":"Gene:59272"},{"id":"A137","pred":"tao:has_database_id","subj":"137","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"r the first steps of infection, the most common treatment approaches focus on disrupting this key event. At present, there are three main strategies to block ACE2 binding: (i) administration of soluble, recombinant ACE2 protein, which acts as a "}